Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesWound CareCapital Bluecross NPWT Coverage & Prior Auth Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedCapital BluecrossPOLICY NUMBER MP 4.004

    Negative Pressure Wound Therapy in the Outpatient Setting

    Customize your policy alerts

    Sign up for Capital Bluecross POLICY NUMBER MP 4.004 alerts

    Get alerted when POLICY NUMBER MP 4.004 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when initiation and continuation of powered NPWT in the outpatient setting are considered medically necessary or investigational for Capital Bluecross members; it applies to clinicians and prior authorization reviewers involved in outpatient wound care.

    Policy Summary
    PayerCapital Bluecross
    PolicyNegative Pressure Wound Therapy in the Outpatient Setting
    Policy CodePolicy POLICY NUMBER MP 4.004
    Change TypeMaterial clinical updatescoding reclassification
    Effective DateOct 1, 2024
    Last ReviewSep 3, 2025
    Next Review Date
    Key ActionDocument objective wound improvement after an initial 2-week NPWT trial to support continuation.
    SourceLink
    POLICY UPDATE CHANGES

    Updated criteria including but not limited to single use devices are now INV and chronic being defined in this policy as greater than 90 days; Procedure codes 97607 and 97608 have been moved to INV coding table.

    Added/deleted ICD-10 codes from New Code Process effective 10/01/2024.

    Changed frequency of monitoring from every 14 days to monthly.

    2 wkinitial trial
    >=90dchronic threshold
    >=30dprior conventional care
    97607/97608codes moved to INV
    nonepediatric clearance

    Coverage Criteria for Outpatient Powered NPWT

    Initial Therapy

    An initial therapeutic trial of not less than 2 weeks using a powered NPWT system may be considered medically necessary when ANY ONE of the following indications is met:

    Initial Indications: Chronic (> 90 days) stage III or IV pressure ulcers that have failed to heal despite optimal wound care when there is high-volume drainage interfering with healing and/or when standard dressings cannot be maintained due to anatomic factors> 90 days

    Part of a comprehensive wound care program addressing modifiable factors (eg, diabetes control, nutrition, pressure relief)

    Initial Indications: Wounds in individuals with underlying clinical conditions known to negatively impact wound healing that are nonhealing (at least 30 days) despite optimal wound care (examples include diabetes, malnutrition, small vessel disease, morbid obesity)>= 30 days

    Malnutrition must be addressed simultaneously with NPWT; part of a comprehensive wound care program

    Policy Summary
    PayerCapital Bluecross
    PolicyNegative Pressure Wound Therapy in the Outpatient Setting
    Policy CodePolicy POLICY NUMBER MP 4.004
    Change TypeMaterial clinical updatescoding reclassification
    Effective DateOct 1, 2024
    Last ReviewSep 3, 2025
    Next Review Date
    Key ActionDocument objective wound improvement after an initial 2-week NPWT trial to support continuation.
    SourceLink
    On This Page
    Coverage Criteria for Outpatient Powered NPWTCoding — Procedure, Supply, and Diagnosis CodesProvider Actions, Prior Authorization, and Documentation RequirementsBackground and Evidence SummaryDefinitions and Device TypesPolicy Revision History
    Initial Indications: Traumatic or surgical wounds with failure of immediate or delayed primary closure AND exposed bone, cartilage, tendon, or foreign material within the woundN/A

    Requires exposed structures or foreign material and inclusion in comprehensive wound care program

    Continuation Therapy

    Continuation of powered NPWT may be considered medically necessary after an initial 2-week therapeutic trial if ALL of the following are met:

    Continuation Conditions: Initial 2-week therapeutic trial resulted in documented objective improvements in the wound2 weeks

    Objective improvements include development/presence of healthy granulation tissue, progressive wound contracture/decreasing depth, and/or commencement of epithelial spread

    Continuation Conditions: There is ongoing objective improvement during subsequent treatmentongoing

    Monitor wound healing at least every 14 days and document objective measures to support continued therapy

    Investigational Continuation Criteria

    Continuation is considered investigational (not supported) when ANY of the following occur:

    Investigational Conditions: The therapeutic trial or subsequent treatment period has not resulted in documented objective improvement in the woundN/A

    Absence of documented objective improvement makes continuation investigational

    Investigational Conditions: The wound has developed evidence of complications that contraindicate continued NPWTN/A

    Includes wound complications that make NPWT unsafe or inappropriate

    Investigational Conditions: The wound has healed to an extent that grafting can be performed or the wound can be anticipated to heal completely with other wound care treatmentsN/A

    When healing eliminates the need for NPWT, continuation is investigational/not supported

    Initial NPWT therapeutic trial criteria

    Covered when ALL of the following are met:

    Initial therapeutic trial: A therapeutic trial of NPWT of not less than 14 days may be considered medically necessary for chronic wounds that have failed to heal despite intense conventional wound therapy for at least 30 days, or for wounds of at least 30 days that have a high probability of failure to heal due to compounding wound and patient factorstrial >=14 days; prior care >=30 days

    Objective evidence of healing is required for continuation beyond the trial period

    Continuation criteria

    Covered for continued use when ALL of the following are met:

    Continuation criteria: For continued use of NPWT beyond 14 days, there must be objective evidence of wound healing (eg, development of healthy granulation tissue and progressive wound contracture) documented in the medical recordobjective improvement documented

    Providers must monitor and document objective improvements at least every 14 days as part of a comprehensive wound care program; lack of objective improvement may render continued therapy not medically necessary

    Contraindications to the use of negative pressure wound therapy (NPWT) include conditions noted by the U.S. Food and Drug Administration: necrotic tissue with eschar, untreated osteomyelitis, nonenteric and unexplored fistulae, malignancy in the wound, exposed nerve, exposed anastomotic site, and exposed organ. The FDA has also reported serious but rare adverse events, most notably bleeding, and infections related to retained dressing pieces; providers should select patients carefully, monitor frequently, and be prepared to intervene promptly for complications. The FDA additionally noted that the safety and effectiveness of NPWT systems have not been established for newborns, infants, and children (no NPWT systems cleared for these populations). Continuation of healing during NPWT should be monitored at a frequency of not less than every 14 days, and complete healing is generally anticipated when bone/cartilage/tendon/foreign material are covered, healthy granulation approaches within 5 mm of the surface, and wound edges are reduced to about 2 cm.

    The policy designates certain procedure codes as investigational and not covered. Specifically, Procedure Codes A9272 and 97607 are listed as investigational and therefore are not covered.

    This document is an excerpt of the outpatient Negative Pressure Wound Therapy policy. Claims and coverage determinations for outpatient NPWT should be evaluated in reference to Policy Number MP 4.004 (Negative Pressure Wound Therapy in the Outpatient Setting); providers should follow that full policy for detailed coverage, coding, and prior-authorization requirements.

    No explicit additional exclusion list is included in the provided excerpt beyond the contraindications noted; the excerpt indicates that comprehensive coverage determinations should refer to the full outpatient NPWT policy (MP 4.004). Policy history in the excerpt documents a consensus review (04/23/2020) but does not add further exclusion conditions in this portion.

    Therapeutic trials of powered NPWT systems for treatment of other acute or chronic wounds not specifically listed in the policy are considered investigational. Use of single-use NPWT systems (powered or nonpowered) for acute or chronic wounds, including but not limited to diabetic, venous, surgical, and traumatic wounds, is considered investigational.

    The evidence base supporting outpatient NPWT for the listed indications consists primarily of randomized controlled trials and systematic reviews; however, these trials are generally low quality and at high risk of bias, with many studies conducted in inpatient settings or limited by small sample sizes, losses to follow-up, or short-term outcomes. Overall, the available RCTs and systematic reviews provide insufficient high-quality evidence to conclusively demonstrate improved net health outcomes for many outpatient indications.

    Within the provided excerpt there is no explicit statement using the phrase ‘not medically necessary’ for specific indications. The excerpt does, however, state investigational stances for therapies and devices not supported by evidence and refers readers to the full outpatient NPWT policy (MP 4.004) for complete determinations.

    Coding — Procedure, Supply, and Diagnosis Codes

    Regulatory/Device Codesmixed
    FDA product code: OMPFDA product classification code for NPWT devices
    Investigational HCPCS/CPT CodesHCPCSNot Covered
    A9272
    97607
    Covered when medically necessary - Procedure/Supply CodesmixedCovered
    97606
    A7000
    A7001
    E2402
    K0743
    K0744
    K0745
    K0746
    97605
    Diagnosis codes (partial list)ICD-10
    E08.621Diabetes mellitus due to underlying condition with foot ulcer
    E08.622Diabetes mellitus due to underlying condition with other skin ulcer
    E09.621Drug or chemical induced diabetes mellitus with foot ulcer
    E09.622Drug or chemical induced diabetes mellitus with other skin ulcer
    E10.621Type 1 diabetes mellitus with foot ulcer
    E10.622Type 1 diabetes mellitus with other skin ulcer
    E11.621Type 2 diabetes mellitus with foot ulcer
    E11.622Type 2 diabetes mellitus with other skin ulcer
    E11.AType 2 diabetes mellitus without complications in remission
    E13.621Other specified diabetes mellitus with foot ulcer
    1–10 of 29
    1/3
    Vascular ulcer diagnoses (I70.*)ICD-10
    I70.643Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle
    I70.644Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot
    I70.645Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot
    I70.648Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg
    I70.65Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration
    I70.731Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh
    I70.732Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf
    I70.733Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle
    I70.734Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot
    I70.735Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot
    1–10 of 14
    1/2
    Varicose/venous ulcer diagnoses (I83.*)ICD-10
    I83.011Varicose veins of right lower extremity with ulcer of thigh
    I83.012Varicose veins of right lower extremity with ulcer of calf
    I83.013Varicose veins of right lower extremity with ulcer of ankle
    I83.014Varicose veins of right lower extremity with ulcer of heel and midfoot
    I83.015Varicose veins of right lower extremity with ulcer other part of foot
    I83.018Varicose veins of right lower extremity with ulcer other part of lower leg
    I83.021Varicose veins of left lower extremity with ulcer of thigh
    I83.022Varicose veins of left lower extremity with ulcer of calf
    I83.023Varicose veins of left lower extremity with ulcer of ankle
    Pressure ulcer diagnoses (L89.*)ICD-10
    L89.003Pressure ulcer of unspecified elbow, stage 3
    L89.004Pressure ulcer of unspecified elbow, stage 4
    L89.013Pressure ulcer of right elbow, stage 3
    L89.014Pressure ulcer of right elbow, stage 4
    L89.023Pressure ulcer of left elbow, stage 3
    L89.024Pressure ulcer of left elbow, stage 4
    L89.103Pressure ulcer of unspecified part of back, stage 3
    L89.104Pressure ulcer of unspecified part of back, stage 4
    L89.113Pressure ulcer of right upper back, stage 3
    Non-pressure chronic ulcer diagnoses (L97.*)ICD-10
    L97.111Non-pressure chronic ulcer of right thigh limited to breakdown of skin
    L97.112Non-pressure chronic ulcer of right thigh with fat layer exposed
    L97.113Non-pressure chronic ulcer of right thigh with necrosis of muscle
    L97.114Non-pressure chronic ulcer of right thigh with necrosis of bone
    L97.115Non-pressure chronic ulcer of right thigh with muscle involvement without evidence of necrosis
    L97.211Non-pressure chronic ulcer of right calf limited to breakdown of skin
    L97.312Non-pressure chronic ulcer of right ankle with fat layer exposed
    L97.313Non-pressure chronic ulcer of right ankle with necrosis of muscle
    L97.314Non-pressure chronic ulcer of right ankle with necrosis of bone
    Other non-pressure chronic ulcer diagnoses (L98.*, L98.A*)ICD-10
    L98.411Non-pressure chronic ulcer of buttock limited to breakdown of skin
    L98.412Non-pressure chronic ulcer of buttock with fat layer exposed
    L98.414Non-pressure chronic ulcer of buttock with necrosis of bone
    L98.423Non-pressure chronic ulcer of back with necrosis of muscle
    L98.43Non-pressure chronic ulcer of abdomen
    L98.A11Non-pressure chronic ulcer of right upper arm (examples of L98.A* series present)
    Listed ICD-10 diagnosis codes (partial list shown in excerpt)ICD-10
    L98.45Non-pressure chronic ulcer of neck
    L98.46Non-pressure chronic ulcer of face
    L98.47Non-pressure chronic ulcer of groin
    L98.491Non-pressure chronic ulcer of skin of other sites limited to breakdown of skin
    L98.492Non-pressure chronic ulcer of skin of other sites with fat layer exposed
    L98.493Non-pressure chronic ulcer of skin of other sites with necrosis of muscle
    L98.494Non-pressure chronic ulcer of skin of other sites with necrosis of bone
    L98.495Non-pressure chronic ulcer of skin of other sites with muscle involvement without evidence of necrosis
    L98.498Non-pressure chronic ulcer of skin of other sites with other specified severity
    L98.ANon-pressure chronic ulcer of upper limb, not elsewhere classified
    1–10 of 24
    1/3
    Listed ICD-10 diagnosis codes (continued)ICD-10
    S31.101DUnspecified open wound of abdominal wall, left upper quadrant without penetration into peritoneal cavity, subsequent encounter
    S31.101SUnspecified open wound of abdominal wall, left upper quadrant without penetration into peritoneal cavity, sequela
    S31.102DUnspecified open wound of abdominal wall, epigastric region without penetration into peritoneal cavity, subsequent encounter
    S31.102SUnspecified open wound of abdominal wall, epigastric region without penetration into peritoneal cavity, sequela
    S31.103DUnspecified open wound of abdominal wall, right lower quadrant without penetration into peritoneal cavity, subsequent encounter
    S31.103SUnspecified open wound of abdominal wall, right lower quadrant without penetration into peritoneal cavity, sequela
    S31.104DUnspecified open wound of abdominal wall, left lower quadrant without penetration into peritoneal cavity, subsequent encounter
    S31.104SUnspecified open wound of abdominal wall, left lower quadrant without penetration into peritoneal cavity, sequela
    S31.105DUnspecified open wound of abdominal wall, periumbilic region without penetration into peritoneal cavity, subsequent encounter
    S31.105SUnspecified open wound of abdominal wall, periumbilic region without penetration into peritoneal cavity, sequela
    1–10 of 16
    1/2
    Listed ICD-10 diagnosis codes (lacerations and related)ICD-10
    S31.116ALaceration without foreign body of abdominal wall, right flank without penetration into peritoneal cavity, initial encounter
    S31.116DLaceration without foreign body of abdominal wall, right flank without penetration into peritoneal cavity, subsequent encounter
    S31.116SLaceration without foreign body of abdominal wall, right flank without penetration into peritoneal cavity, sequela
    S31.117ALaceration without foreign body of abdominal wall, left flank without penetration into peritoneal cavity, initial encounter
    S31.117DLaceration without foreign body of abdominal wall, left flank without penetration into peritoneal cavity, subsequent encounter
    S31.117SLaceration without foreign body of abdominal wall, left flank without penetration into peritoneal cavity, sequela
    S31.126ALaceration with foreign body of abdominal wall, right flank without penetration into peritoneal cavity, initial encounter
    S31.126DLaceration with foreign body of abdominal wall, right flank without penetration into peritoneal cavity, subsequent encounter
    S31.126SLaceration with foreign body of abdominal wall, right flank without penetration into peritoneal cavity, sequela
    S31.127ALaceration with foreign body of abdominal wall, left flank without penetration into peritoneal cavity, initial encounter
    Listed ICD-10 diagnosis codes (puncture wounds, surgical wound complications)ICD-10
    S31.136APuncture wound of abdominal wall without foreign body, right flank without penetration into peritoneal cavity, initial encounter
    S31.136DPuncture wound of abdominal wall without foreign body, right flank without penetration into peritoneal cavity, subsequent encounter
    S31.137APuncture wound of abdominal wall without foreign body, left flank without penetration into peritoneal cavity, initial encounter
    S31.137DPuncture wound of abdominal wall without foreign body, left flank without penetration into peritoneal cavity, subsequent encounter
    S31.13AAPuncture wound of abdominal wall without foreign body, unspecified flank without penetration into peritoneal cavity, initial encounter
    T81.31XADisruption of external operation (surgical) wound, initial encounter
    T81.31XDDisruption of external operation (surgical) wound, subsequent encounter
    T81.320ADisruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, initial encounter
    T81.320DDisruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, subsequent encounter
    Listed ICD-10 diagnosis codes (surgical site infections and wound disruptions)ICD-10
    T81.320SDisruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, sequela
    T81.328SDisruption or dehiscence of closure of other specified internal operation (surgical) wound, sequela
    T81.329ADeep disruption or dehiscence of operation wound, unspecified, initial encounter
    T81.329DDeep disruption or dehiscence of operation wound, unspecified, subsequent encounter
    T81.329SDeep disruption or dehiscence of operation wound, unspecified, sequela
    T81.33XADisruption of traumatic injury wound repair, initial encounter
    T81.33XDDisruption of traumatic injury wound repair, subsequent encounter
    T81.42XAInfection following a procedure, deep incisional surgical site, initial encounter
    T81.42XDInfection following a procedure, deep incisional surgical site, subsequent encounter
    T81.49XAInfection following a procedure, other surgical site, initial encounter
    1–10 of 11
    1/2
    Reclassified Procedure CodesCPT
    97607procedure code moved to INV coding table
    97608procedure code moved to INV coding table
    Therapeutic trial duration
    Therapeutic trial durationA therapeutic trial of NPWT of not less than 14 days (>= 14 days) is required to consider therapy medically necessary.
    Continuation requirementFor continued use beyond the initial trial, objective evidence of wound healing (e.g., healthy granulation tissue, wound contracture) must be documented.
    Monitoring frequency (related)Monitor healing at least every 14 days during subsequent treatment per policy documentation requirements.
    Prior conventional therapy duration
    Prior conventional therapy duration>= 30 days of intense conventional wound therapy is required before a therapeutic trial of NPWT for chronic wounds.
    When appliesApplies to chronic wounds that have failed to heal despite intense conventional care for at least 30 days or wounds of ≥30 days with high probability of failure.
    DocumentationPatient record must document prior conventional wound care and lack of healing to support NPWT initiation.
    Ulcer stage / severity
    Ulcer stages referencedPolicy uses pressure ulcer staging (Stage III and Stage IV) to guide selection of diagnosis codes and appropriateness for NPWT.
    Muscle/bone involvementCodes/descriptions include severity modifiers indicating muscle or bone involvement (e.g., necrosis of muscle or bone) that should be used when selecting ICD-10 codes.
    Use for code selectionSelect the ICD-10 code that reflects both anatomic site and stage/severity (stage 3, stage 4, unstageable as described in staging definitions).
    Chronic — policy definition
    Chronic definition (policy)Chronic is defined in this policy as greater than 90 days (> 90 days).
    Context of useThe chronic definition is applied when considering NPWT for chronic pressure ulcers that have failed to heal despite prior care.
    Policy history notePolicy update (03/06/2025) explicitly defines chronic as greater than 90 days in the record of revisions.

    Provider Actions, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Prior authorization requirement: initial ≥2‑week trial; continuation needs documentation

    An initial therapeutic trial of powered NPWT of not less than 2 weeks is required for initiation; continuation beyond this initial 2‑week trial requires documented objective improvement in the wound (see continuation criteria).

    • Initial trial duration: not less than 2 weeks (>=14 days).
    • Continuation requires documentation of objective improvements (granulation tissue, progressive wound contracture/decreasing depth, or epithelial spread).
    Billing Rule

    Coverage and investigational code summary; follow coding table

    Use the policy's coding tables: certain HCPCS/CPT procedure and supply codes are designated investigational/not covered (e.g., A9272, 97607) while others are listed as covered when medically necessary (e.g., 97606, A7000/A7001, E2402, K0743–K0746, 97605). Prior authorization and billing must follow the coding table classifications in the policy.

    • Investigational / not covered examples: A9272; 97607.
    • Covered-when-medically-necessary examples: 97606, A7000/A7001, E2402, K0743–K0746, 97605.
    Note

    Follow outpatient NPWT policy MP 4.004 for adjudication

    Adjudication and any prior authorization determinations should follow the full outpatient NPWT policy (Policy Number MP 4.004); this excerpt cross-references that policy for complete clinical rules and coverage logic.

    • Policy reference: POLICY NUMBER MP 4.004 (Negative Pressure Wound Therapy in the Outpatient Setting).
    Prior Authorization

    Prior authorization — consult full policy for PA steps/forms

    This excerpt does not state the complete prior authorization process or specific forms; providers must consult the full MP 4.004 policy and payer prior‑authorization resources for explicit PA steps and required documentation.

    • Full prior authorization steps and forms are in the complete policy and payer PA guidance (not included in this excerpt).
    Prior Authorization

    Prior authorization / coding reclassification: 97607 & 97608 moved to INV

    Procedure codes 97607 and 97608 were reclassified to the investigational (INV) coding table as of the 03/06/2025 update; this reclassification may change prior authorization outcomes and claim adjudication.

    • 03/06/2025 minor review: "Procedure codes 97607 and 97608 have been moved to INV coding table."
    Documentation Required

    Adjunctive care requirement: NPWT as part of comprehensive wound care

    Powered NPWT must be used as part of a comprehensive wound care program that addresses modifiable factors such as diabetes control, nutritional status, and relief of pressure; documentation should show these adjunctive measures were considered and managed.

    • Comprehensive wound care includes evaluation and wound measurements by a licensed medical professional, dressings to maintain a moist environment, debridement when present, and evaluation/provision for nutrition and vascular status.
    • Examples of modifiable factors: diabetes control, nutrition, pressure relief.
    Step Therapy

    Prior conservative therapy requirement: conventional care ≥30 days before NPWT trial

    For chronic wounds, a therapeutic trial of intense conventional wound therapy for at least 30 days is expected before considering NPWT; NPWT may then be trialed for not less than 14 days if the wound has failed to heal despite prior care.

    • Prior conservative therapy: intense conventional wound therapy ≥30 days for chronic wounds that have failed to heal.
    • Therapeutic trial of NPWT thereafter: not less than 14 days.
    Note

    Placeholder — consult full document where inventory is empty

    This callout is a placeholder referencing inventory entries with no chunk indices; consult the full policy source (MP 4.004) for any additional provider actions not captured in this excerpt.

    • Fallback: review the complete policy document for missing details.
    Step Therapy

    Step therapy absence in excerpt

    No step therapy requirements are specified in this excerpt of the policy.

    • The excerpt explicitly notes that no step therapy requirements are specified here.
    Note

    Placeholder — additional policy details in full document

    This callout is a placeholder for inventory entries lacking excerpt content; providers should reference the full MP 4.004 policy when preparing prior authorization or appeals.

    • Use the full policy for comprehensive requirements and examples.
    Documentation Required

    Required clinical documentation and monitoring: objective improvements after initial 2‑week trial

    Providers must document objective improvements after the initial 2‑week therapeutic trial and monitor healing at least every 14 days (unless otherwise specified in payer guidance); objective signs include healthy granulation tissue, progressive wound contracture/decreasing depth, and epithelial spread.

    • Monitoring frequency: continuation of healing should be monitored not less than every 14 days.
    • Objective improvement examples: development/presence of healthy granulation tissue, progressive wound contracture/decreasing depth, commencement of epithelial spread.
    Documentation Required

    Comprehensive wound care documentation required

    Document a licensed medical professional's evaluation, wound measurements, dressing application, and any debridement performed; include nutrition and vascular status assessments as part of the comprehensive wound care record.

    • Minimum documentation elements: licensed clinician evaluation, wound measurements, dressing details, debridement records, and nutritional/vascular assessments.
    Documentation Required

    Objective healing documentation required for continuation

    Record objective evidence of response to therapy—such as healthy granulation tissue formation and progressive wound contracture—to justify continued NPWT beyond the initial therapeutic trial.

    • Objective healing documentation is required for continued coverage beyond 14 days.
    Billing Rule

    Diagnosis code list for documentation: reference I70.*, I83.*, I87.*, L89.*, L97.*, L98.*

    Include appropriate ICD-10 diagnosis codes when submitting documentation and claims; the policy lists code blocks such as I70.*, I83.*, I87.*, L89.*, L97.*, and L98.* that correspond to vascular, venous, pressure, and non‑pressure chronic ulcer diagnoses.

    • Diagnosis code groups referenced: I70.* (vascular ulcers), I83.* (varicose/venous ulcers), I87.*, L89.*, L97.*, L98.*.
    Billing Rule

    Extensive ICD‑10 code list included — reference codes like L98.*, S31.*, T81.*

    The policy contains an extensive ICD-10 list (including L98.* series, S31.* and T81.* codes) that should be used to support documentation and claims for NPWT initiation and continuation in the outpatient setting.

    • Examples include L98.* series (other non‑pressure chronic ulcers), S31.* (open wounds of abdominal wall), and T81.* (surgical wound disruptions/infections).
    Billing Rule

    Administrative ICD‑10 update effective 10/01/2024 — use current codes

    Policy history documents administrative ICD‑10 code updates effective 10/01/2024; ensure current diagnosis codes are used on claims and supporting documentation.

    • 08/15/2024 Administrative Update: Added/deleted ICD‑10 codes from New Code Process; effective date 10/01/2024.
    Denial Risk

    Triggers for denial of continuation: lack of documented objective improvement or contraindicating complications

    Continuation may be denied (considered investigational) when the therapeutic trial or subsequent treatment period has not produced documented objective improvement, when complications contraindicate continued NPWT, or when the wound has healed sufficiently for grafting or alternative treatments.

    • Trigger examples for denial: lack of documented objective improvement; wound complications that contraindicate NPWT; wound healed to permit grafting or other care.
    Prior Authorization

    Requirement for continued coverage: objective evidence of healing beyond 14 days

    For continued coverage beyond the 14‑day trial, providers must supply objective evidence of wound healing (e.g., healthy granulation tissue, progressive wound contracture); absence of these findings may render continued NPWT not medically necessary.

    • Required evidence: development of healthy granulation tissue and progressive wound contracture during continued treatment.
    Note

    Policy reference: claims evaluated against MP 4.004

    Claims and coverage decisions may be evaluated against Policy Number MP 4.004 (Negative Pressure Wound Therapy in the Outpatient Setting); reference this policy number in PA submissions and appeals.

    • Policy reference to include on submissions: MP 4.004.
    Denial Risk

    Diagnostic coding mismatch risk: ensure codes match listed ICD‑10 diagnoses

    Diagnostic codes that do not match the policy's listed ICD‑10 codes or clinical documentation that lacks a supported wound diagnosis may trigger claim denial; ensure the diagnosis and supporting records align with the codes enumerated in the policy.

    • Mismatch risk: using diagnosis codes not listed (or failing to document a supported wound diagnosis) may lead to denial.
    Denial Risk

    Coding change denial risk: 97607/97608 reclassification may affect adjudication

    Changes to coding (for example, moving procedure codes 97607 and 97608 to the investigational table) can affect claim adjudication and may trigger denials if billing teams use outdated code tables; notify billing teams of these reclassifications.

    • 03/06/2025 minor review note: "Procedure codes 97607 and 97608 have been moved to INV coding table."
    • Advise billing: update code lists and prior authorization templates to reflect reclassifications.

    Background and Evidence Summary

    Negative pressure wound therapy (NPWT) is a wound treatment modality that applies controlled suction to remove fluid, debris, and infectious material from a wound bed to promote granulation tissue formation and wound contraction. The mechanism is thought to include removal of interstitial fluid and reduction of edema, increased local blood flow and vascularity, and mechanical forces that may stimulate cellular proliferation and tissue growth. NPWT may be used adjunctively to surgery or as an alternative for patients who are not surgical candidates; both powered/electrically driven devices and portable single-use mechanical systems are described in the policy.

    The evidence base for outpatient NPWT is characterized by randomized trials and systematic reviews but is generally judged to be of low quality with high risk of bias. For chronic pressure ulcers and for lower-extremity venous ulcers, trials have been small, often conducted in inpatient settings, and have not provided consistent high-quality evidence of improved long-term outcomes such as complete wound closure. Studies of portable single-use devices have shown noninferiority for wound-area reduction in some trials, but limitations including loss to follow-up, lack of appropriate control groups, and limited outpatient data mean that the evidence remains insufficient to draw firm conclusions about net clinical benefit in the outpatient setting.

    Definitions and Device Types

    Nonpowered (mechanical) NPWT system
    DefinitionA portable, fully disposable system (e.g., SNaP/PICO) that uses a cartridge or mechanical means to generate negative pressure without a powered pump.
    ComponentsTypically consists of a cartridge, dressing, and strap; cartridge acts as the negative pressure source.
    Use settingDesigned to be lightweight and wearable; may be used as patients transition from inpatient to outpatient settings.
    NPWT with instillation
    DefinitionNPWT devices designed to allow controlled delivery and drainage of topical antiseptic or antimicrobial wound treatment solutions (instillation).
    Example deviceV.A.C. VERAFLO Therapy device (3M/KCI/Acelity) cleared by FDA for instillation use.
    Intended use noteInstillation systems are typically used with compatible NPWT units and may have limitations for home care settings (per device indications).
    Comprehensive wound care program
    DefinitionA comprehensive wound care program includes documentation by a licensed medical professional, application of dressings to maintain a moist wound environment, debridement of necrotic tissue when present, and evaluation/provision for adequate nutritional and vascular status.
    Documentation requirementPatient medical record must contain evaluation, care, and wound measurements performed by a licensed clinician.
    Adjunctive measuresProgram addresses modifiable factors (e.g., nutrition, vascular status) concurrently with NPWT as part of overall care.
    Granulating tissue
    DefinitionGranulating tissue is the formation of granule-like projections on the internal surface of the wound representing outgrowth of new capillaries and promoting healing.
    Clinical significancePresence of healthy granulation tissue is an objective sign of wound healing required to justify continuation of NPWT beyond the initial trial.
    Examples of documentationClinicians should document granulation tissue formation, wound contracture/decreasing depth, or epithelial spread as evidence of response.
    Pressure (decubitus) ulcer staging
    DefinitionPressure (decubitus) ulcers are classified into Stages I–IV and an unstageable category, ranging from non-blanchable erythema (Stage I) to full-thickness tissue loss with exposed bone/tendon/muscle (Stage IV), and unstageable when the base is obscured by slough or eschar.
    Stage IIIFull-thickness tissue loss; subcutaneous fat may be visible but bone, tendon, or muscle are not exposed.
    Stage IV and unstageableStage IV involves exposed bone/tendon/muscle; unstageable ulcers have base obscured by slough/eschar until debridement reveals true depth.
    Non-pressure chronic ulcer (L97.*)
    DefinitionNon-pressure chronic ulcers are represented by the ICD-10 L97.* series, describing chronic lower-extremity ulcers with varying severity from skin breakdown to muscle or bone necrosis.
    Severity descriptorsL97 codes include modifiers for tissue involvement (e.g., limited to breakdown of skin, fat layer exposed, necrosis of muscle, necrosis of bone).
    Use in documentationSelect the specific L97.* code that reflects anatomic site and severity when documenting chronic non-pressure ulcers for NPWT consideration.
    Pressure ulcer (L89.*)
    DefinitionPressure ulcers correspond to the ICD-10 L89.* series, which specify pressure ulcer diagnoses by anatomic site and stage.
    Code selectionChoose the L89.* code that matches the ulcer site and stage (e.g., L89.003 = pressure ulcer unspecified elbow, stage 3; L89.004 = stage 4).
    Relationship to NPWTStage and site coding informs medical necessity determinations for NPWT in pressure ulcers (especially Stage III–IV).
    Negative pressure wound therapy (NPWT)
    DefinitionNegative pressure wound therapy (NPWT) is a wound treatment modality that uses suction to remove fluid, debris, and infectious material to promote granulation tissue and wound healing and includes both powered (electrically driven) systems and mechanically powered single-use/portable systems.
    Clinical usesNPWT may be used as an adjunct to surgical therapy or as an alternative in debilitated patients and is applied in inpatient and outpatient settings.
    Device variabilityDevices vary from large powered units to disposable mechanical systems; regulatory clearances and technologies (e.g., instillation) differ by device.
    Greater than 90 days — 'chronic' definition
    Definition (chronic threshold)This policy defines chronic as greater than 90 days (> 90 days) when applying chronic wound criteria for NPWT.
    ApplicationThe >90-day definition is used to identify chronic pressure ulcers and other chronic wounds that may qualify for NPWT after failed conventional care.
    Policy updateThe explicit >90 days chronic definition was added in the 03/06/2025 policy update noted in policy history.

    Policy Revision History

    2025-09-03administrative_updateLatest

    Added ICD-10 codes via administrative update.

    2025-06-16administrative_update

    Removed Benefit Variations section and updated Disclaimer.

    2025-03-06minor_review_material_change

    Minor review updated criteria including reclassification of single-use devices to investigational and defined 'chronic' as greater than 90 days; procedure codes 97607 and 97608 moved to the investigational coding table.

    2024-08-15administrative_update

    Administrative update adding and deleting ICD-10 codes from the New Code Process effective 10/01/2024.

    2024-03-27consensus_review

    Consensus review updated cross-references, background, rationale, and references with no changes to coding.

    2023-02-15consensus_review

    Consensus review updated description/background, coding table, and references.

    2022-03-07consensus_review

    Consensus review updated the summary of evidence, FEP, and references with no changes to policy statement.

    2021-02-12minor_review

    Minor review changed monitoring frequency from every 14 days to monthly and removed Length of Coverage section; no changes to coding.

    2020-04-23consensus_review

    Consensus review; policy statements remained unchanged as noted in policy history.